BioInnovation Institute (BII), an international enterprise foundation with a non-profit objective incubating and accelerating world-class life science research, announces today that it has accepted a new project into its Bio Studio program. Based on recent breakthroughs in Artificial Intelligence (AI) and protein design, the project is creating a new class of therapeutic proteins to modulate […]
For those that were unable to attend on Optimum’s 14th Annual Healthcare Investor Conference, or indeed would like a recap of what was shared on the day, we have been releasing the top takeaways from the panels! Our first panel of the day, chaired by Stephen Hansen, from BioCentury, saw a panel of blue chip […]
We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]
We were privileged to hear visionary insights during Mike Ward’s fascinating fireside chat with Werner Lanthaler, CEO of Evotec. In the discussion, he asked Werner to share his views about the sector and big macro issues, as well as what it takes to build a biotech. This is what we learned: The teenage Werner wanted […]
Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta B.V. (‘Gadeta’), an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors, today announced the formation of a Scientific Advisory Board comprised of internationally renowned leaders in oncology, T cell biology and strategic drug development. The Scientific […]
